OncoMatch/Clinical Trials/NCT06509009
Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Is NCT06509009 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Nimotuzumab for nasopharyngeal carcinoma by ajcc v8 stage.
Treatment: Nimotuzumab — The goal of this study is to learn the efficacy and safety of nimotuzumab combined with toripalimab and gemcitabine/cisplatin regimen treatment recurrent/distant-metastasis nasopharyngeal carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: EGFR expression positive
EGFR expression positive
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiotherapy
Subjects who have received radiotherapy ... within the past six months
Cannot have received: chemotherapy
Subjects who have received ... chemotherapy ... within the past six months
Cannot have received: immunosuppressive agents
Subjects who have received ... immunosuppressive agents ... within the past six months
Cannot have received: monoclonal antibodies
Subjects who have received ... monoclonal antibodies ... within the past six months
Cannot have received: EGFR tyrosine kinase inhibitor
Subjects who have received ... oral epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) ... within the past six months
Cannot have received: anti-angiogenic drugs
Subjects who have received ... anti-angiogenic drugs within the past six months
Lab requirements
Blood counts
white blood cell count ≥ 3 × 10^9/l; absolute neutrophil count ≥ 1.5 × 10^9/l; platelet count ≥ 100 × 10^9/l; hemoglobin level ≥ 90 g/l
Kidney function
serum creatinine level ≤ 1.2 mmol/l or creatinine clearance ≥ 60 ml/min
Liver function
serum total bilirubin ≤ 1.5 × uln (in case of liver metastasis, ≤ 3.0 × uln); ast and alt ≤ 2.5 × uln (in case of liver metastasis, ≤ 5.0 × uln)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify